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Background—We hypothesized that normal and pathological vessel walls display a differential pattern of secreted proteins. We
have recently set up the conditions for comparing secretomes from carotid atherosclerotic plaques and control arteries using
a proteomic approach to assess whether differentially secreted proteins could represent markers for atherosclerosis.
Methods and Results—Normal endartery segments and different regions of endarterectomy pieces (noncomplicated/
complicated plaques) were incubated in protein-free medium, and the released proteins were analyzed by 2D
electrophoresis (2-DE). Among the differently secreted proteins, we have identified heat shock protein-27 (HSP27).
Surprisingly, compared with control arteries, HSP27 release was drastically decreased in atherosclerotic plaques and
barely detectable in complicated plaque supernatants. HSP27 was expressed primarily by intact vascular cells of normal
arteries and carotid plaques (immunohistochemistry). Plasma detection of soluble HSP27 showed that circulating HSP27
levels are significantly decreased in the blood of patients with carotid stenosis relative to healthy subjects (0.19 [0.1 to
1.95] versus 83 [71.8 to 87.8]) ng/mL, P0.0001).
Conclusions—HSP27 secretion is decreased in complicated atherosclerotic plaques, and sHSP27 plasma levels are
decreased in atherosclerotic patients compared with healthy subjects. Plasma sHSP27 levels could be a potential index
of atherosclerosis, although further validation is needed in large patient cohorts. (Circulation. 2004;110:2216-2219.)
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Atherothrombosis is the leading cause of death in developedcountries. Beyond the classic risk factors (dyslipidemias,
diabetes, and hypertension), humoral markers of plaque vulner-
ability related primarily to inflammation (eg, high-sensitivity
C-reactive protein, interleukin-6, -10, and -18, CD40L) or
reflecting pathological vascular remodeling (eg, immune activa-
tion, apoptosis, extracellular matrix degradation) have recently
been highlighted.1 Emerging noninvasive imaging techniques
for assessment of subclinical atherosclerosis permit measure-
ment of intima-media thickness or peripheral flow-mediated
dilatation, which are inversely correlated with coronary artery
diseases.2 Despite these achievements, intermediate phenotypes
between risk factors and clinical complications are needed to
target vulnerable patients.3 We hypothesized that the patterns of
protein secretion are different between atherosclerotic plaques
and normal endarteries. Whereas the existing markers were
found by monitoring the variations of a candidate protein related
to the pathology, our strategy is to compare the secretome from
normal and pathological arteries using a differential proteomic
approach to identify new biological markers potentially released
by the arterial wall within the plasma.4 The incubation of
complicated and noncomplicated endarterectomy samples or
control endarteries in a serum-free culture medium allowed us to
harvest separately the proteins released from lesioned and
healthy areas. Two-dimensional electrophoresis (2-DE) enabled
us to analyze these secretomes globally and to identify, among
the differentially secreted proteins, heat shock protein 27
(HSP27) as a potential marker of atherosclerosis. Confirming
these results, plasma HSP27 was markedly decreased in athero-
sclerotic patients relative to healthy subjects.
Methods
Tissue Sampling
Twenty-eight patients (carotid stenosis 70%, 21 men/7 women;
age, 689 years; 86% hypertensive, 39% diabetic, 54% hyperlipid-
emic) undergoing carotid endarterectomy at our institutions were
included. Informed consent was obtained before enrollment. Blood
samples were collected from these patients the day of endarterecto-
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my and from 12 healthy volunteers without significant differences
for sex (6 men/6 women) and age (628 years). Conditioned media
from 36 control endarteries (24 mammary, 12 radial) and 35
atherosclerotic endarterectomies (10 femoral, 25 carotids) were
collected. The study was approved by the local Ethical Committees
in accordance with institutional guidelines.
Tissue Culture
Carotid endarterectomy samples were dissected as described previous-
ly,4 separating the stenosing complicated zone (origin of the internal
carotid artery) from the adjacent plaque (common and external carotid
endartery). Histological analysis showed that complicated plaques had
ruptured and contained an intraplaque hemorrhage with a variable but
important proportion of inflammatory cells. The adjacent area, consid-
ered noncomplicated plaque, was composed of fibrous thickening with
a variable content of vascular smooth muscle cells (VSMCs). Femoral
endarterectomies exhibited a high degree of calcification but no in-
traplaque hemorrhage. For mammary and radial arteries, the adventitia
was removed before incubation of the intima-media. Samples were cut
and incubated separately for 24 hours in serum-free RPMI medium at
37°C. Conditioned media were collected and centrifuged, and protein
concentration was determined by Bradford’s method. Tissue secretion
attributed to necrosis during the incubation period was 10% as
assessed by LDH release.
Proteomic Analysis
Conditioned media (600 g of protein) were precipitated by use of
10% trichloroacetic acid in acetone with 0.07% 2-mercaptoethanol
(1 hour,20°C) and washed with cold acetone (20°C, 20 minutes)
before 2-DE was performed. The spots of interest were treated as
described previously.4 The peptides were analyzed in a Voyager DE
STR MALDI-TOF mass spectrometer (Perspective Biosystem).
Proteins were identified by use of the MASCOT program and
comparing with SWISS-PROT and NCBI protein sequence data-
bases. Phosphopeptides were characterized by liquid chromatogra-
phy electrospray ionization tandem mass spectrometry (LC-MS/MS)
and by immobilized metal affinity chromatography (IMAC)5 com-
bined with MALDI Q-TOF MS/MS.6
Western Blot
Equal amounts of conditioned-medium proteins (15 g) were loaded
into a 12% polyacrylamide gel and electrophoresed as described
previously.7 Blots were incubated with anti-HSP27 (sc-9012, Santa
Cruz), anti-HSP60 (sc-1052), and anti-HSP70 (SPA-812 Stressgen)
antibodies.
ELISA
Plasma and tissue conditioned media levels of soluble HSP27 (sHSP27)
were measured with a commercially available kit (Oncogene).
Immunohistochemistry
Specimens were fixed with paraformaldehyde and embedded in paraf-
fin, and immunohistochemistry was performed on 4-m sections as
described previously7 using polyclonal goat anti-human HSP27 anti-
body (sc-1049) and anti–SMC--actin (clone 1A4, Dako).
Statistical Analysis
Statistical analysis was performed with SPSS 8.0. ELISA data are
expressed as medians and interquartile ranges and were analyzed by
the Mann-Whitney test. Differences between noncomplicated and
complicated plaques were analyzed by Wilcoxon paired test.
Results
HSP27 Secretion Is Drastically Decreased
in Atherosclerosis
The 2-DE analysis of the secretomes of carotid endarterecto-
my samples versus control mammary endarteries led us to the
identification of HSP27 by MS, as differentially secreted
from both arteries (Figure 1, A and B). HSP27 isoforms were
characterized by LC-MS/MS analysis. Signals corresponding
to the peptide QLpS82SGVSEIR (m/z, 578.24 [2]) for
HSP27 protein in spot 1 and QLS82SGVSEIR (m/z, 538.25
[2]) in spot 2 demonstrated that HSP27 in spot 1 was
phosphorylated. These results were confirmed by IMAC and
MALDI MS/MS sequencing.5,6
Western blot analysis showed that HSP27 secretion is
lower in atherosclerotic plaques (femoral, F; carotid noncom-
plicated plaques, NCP; carotid complicated plaques, CP)
compared with control arteries (mammary, M; radial, R)
(Figure 1, C and D). These data were confirmed by quanti-
tative ELISA: M, 1243 (734–1909); R, 910 (505–2508); F,
303 (138-526); NCP, 315 (119-515); CP, 33 (17-111) (Figure
1D). We tested the secretion of other HSPs and found a
diminished sHSP70 level in atherosclerotic samples, whereas
sHSP60 showed the opposite pattern (Figure 1C). Whereas
HSP60/70 exhibited a diffuse trend, diminished HSP27 re-
lease was clearly correlated to the complexity of the plaque.
Plasma HSP27 Is Decreased in Atherosclerotic
Patients Relative to Healthy Subjects
To confirm our hypothesis that plasma protein content can
reflect arterial wall secretion, we measured sHSP27 level in
the plasma of patients with carotid stenosis and healthy
controls. Circulating HSP27 levels were decreased 20-fold in
patients with carotid atherosclerosis relative to healthy sub-
jects (0.19 [0.1 to 1.95] versus 83 [71.8 to 87.8] ng/mL,
P0.0001) (Figure 1D).
Tissue HSP27 Immunostaining
By immunohistochemistry, we found that both human ath-
erosclerotic plaques and mammary arteries expressed HSP27
protein. Immunostaining for HSP27 (Figure 2, A and C) and
SMC--actin (B and D) in serial tissue sections showed that
HSP27 was expressed primarily by VSMCs.8 No staining was
obtained in negative controls (not shown).
Discussion
In a preliminary study, we have validated an original approach
analyzing the secreted proteomes from atherosclerotic plaques and
nonpathological arterial wall by 2-DE: incubation of the tissue in a
serum-free medium allows the accumulation of proteins and their
subsequent analysis without interference of plasma proteins.4 In the
present study, using the same procedure, we have identified HSP27,
for which production by the arterial wall correlates negatively with
atherosclerotic plaque complexity.
HSPs are ubiquitous proteins serving as molecular chaperones,
and their cytoprotective functions rely on intracellular mechanisms.
HSPs can also be secreted and released into the bloodstream, where
their role in this soluble form remains unknown. In cardiovascular
diseases, HSP expression is modulated both at the lesion site and
in plasma.9–12 HSP70 has been suggested to protect VSMCs
from oxidative aggression.13 Furthermore, increased levels of
sHSP70 have been correlated with decreased intima/media
thickness11 and with low risk of coronary artery disease.14
HSP60 was detected in aorta and carotid arteries, correlating
with atherosclerosis severity.15 Moreover, sHSP60 could be a
marker of atherosclerosis.9,10 To the best of our knowledge,
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Figure 1. HSP27 secretion: from arterial wall to plasma. 2D gels of secretomes from control endartery (A) and complicated plaque (B).
Circles show 2 spots corresponding to HSP27, corresponding to different phosphorylation states. C, Western blot for HSP27, HSP60,
and HSP70 in conditioned media samples (#, subject/patient number). D, sHSP27 quantification by ELISA. Left, Conditioned media
samples (HSP27 levels normalized by protein concentration; *P0.005 M, R vs F, NCP; †P0.0001 M, R, F, NCP vs CP). Inset, corre-
sponding Western blot for HSP27. Right, plasma levels of atherosclerotic patients (n28) and controls (n12) (*P0.0001). Boxes rep-
resent 25th and 75th percentiles; line within boxes, median. Error bars mark 10th and 90th percentile.
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nothing has yet been reported on HSP27 in atherosclerosis.
HSP27 is expressed by both endothelial cells and VSMCs and is
able, in its phosphorylated form, to bind and stabilize actin
microfilaments, favoring the formation of actin stress fibers.16
We have shown that HSP27 colocalizes with VSMCs in human
atherosclerotic plaques and mammary arteries, probably as a
physiological response to hemodynamic or biomechanical stress.
Indeed, hemodynamic stress increases the expression of HSP27
in VSMCs.8 Pharmacological induction of HSP27 attenuates
intimal hyperplasia in vivo.17 HSP27 could also interfere with
the atherosclerotic inflammatory response by inhibiting nuclear
factor-B activation.18 Finally, HSP27 can downregulate the
apoptotic signaling pathway19 and could thus contribute to
stabilize atherosclerotic lesions. We show for the first time that
HSP27 is secreted by the undiseased vascular wall and that its
release markedly diminishes according to the complexity of the
plaque. Although this differential secretion does not seem to be
specific for a vascular territory, because both mammary and
radial endarteries secrete a higher amount of HSP27 than carotid
or femoral atherosclerotic endarterectomies, this possibility can-
not be excluded. Moreover, whereas sHSP27 is detected in the
blood of 100% of healthy individuals, sHSP27 levels were
almost undetectable in a large number of atherosclerotic patients.
Despite a limited number of patients analyzed in this study, the
marked statistical significance confers considerable value to our
findings.
The cause and the biological significance of this important
diminution of plasma HSP27 in atherosclerotic patients remain
to be elucidated. Whether soluble HSP27 has an atheroprotective
role or whether it is the reflection of a pathological vascular
remodeling process is not known and requires further investiga-
tion. Our results strongly suggest that low levels of plasma
HSP27 could serve as a potential marker for atherosclerosis and
should be validated in larger cohorts.?
Disclosure
The authors are named as coinventors on pending patents filed by the
Fundaicion Jimenez Diaz that relate to the use of biomarkers on
cardiovascular disease.
Acknowledgments
This study was supported by Pfizer-Spain, Cardiovascular Network
(03/01), Fundacion Española del Corazon, SAF 2001/0717, CAM
08.4/0021.1-2003, European Network (QLG1-CT-2003-01215), IN-
DAS, INSERM, and the Leducq Foundation.
References
1. Libby P, Ridker PM. Novel inflammatory markers of coronary risk:
theory versus practice. Circulation. 1999;100:1148–1150.
2. Bisoendial RJ, Hovingh GK, de Groot E, et al. Measurement of sub-
clinical atherosclerosis: beyond risk factor assessment. Curr Opin
Lipidol. 2002;13:595–603.
3. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable
patient: a call for new definitions and risk assessment strategies, I.
Circulation. 2003;108:1664–1672.
4. Duran MC, Mas S, Martin-Ventura JL, et al. Proteomic analysis of human
vessels: application to atherosclerotic plaques. Proteomics. 2003;3:973–978.
5. Stensballe A, Andersen S, Jensen ON. Characterization of phosphoproteins from
electrophoretic gels by nanoscale Fe(III) affinity chromatography with off-line
mass spectrometry analysis. Proteomics. 2001;1:207–222.
6. Bennett KL, Stensballe A, Podtelejnikov AV, et al. Phosphopeptide
detection and sequencing by matrix-assisted laser desorption/ionization
quadrupole time-of-flight tandem mass spectrometry. J Mass Spectrom.
2002;37:179–190.
7. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, et al.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease
Fas ligand expression and cytotoxicity in activated human T lymphocytes.
Circulation. 2003;108:1506–1513.
8. McGregor E, Kempster L, Wait R, et al. F-actin capping (CapZ) and other
contractile saphenous vein smooth muscle proteins are altered by hemodynamic
stress: a proteomic approach. Mol Cell Proteomics. 2004;3:115–124.
9. Pockley AG, Wu R, Lemne C, et al. Circulating HSP60 is associated with
early cardiovascular disease. Hypertension. 2000;36:303–307.
10. Xu Q, Schett G, Perschinka H, et al. Serum soluble HSP60 is elevated in
subjects with atherosclerosis in a general population. Circulation. 2000;
102:14–20.
11. Pockley AG, Georgiades A, Thulin T, et al. Serum HSP70 levels predict
the development of atherosclerosis in subjects with established hyper-
tension. Hypertension. 2003;42:235–238.
12. Pockley AG. Heat shock proteins, inflammation, and cardiovascular
disease. Circulation. 2002;105:1012–1017.
13. Johnson AD, Berberian PA, Tytell M, et al. Differential distribution of
70-kD heat shock protein in atherosclerosis: its potential role in arterial
SMC survival. Arterioscler Thromb Vasc Biol. 1995;15:27–36.
14. Zhu J, Quyyumi AA, Wu H, et al. Increased serum levels of heat shock
protein 70 are associated with low risk of coronary artery disease. Arte-
rioscler Thromb Vasc Biol. 2003;23:1055–1059.
15. Kleindienst R, Xu Q, Willeit J, et al. Immunology of atherosclerosis:
demonstration of HSP60 expression and T-lymphocytes bearing
alpha/beta or gamma/delta receptor in human atherosclerotic lesions.
Am J Pathol. 1993;142:1927–1937.
16. Bitar KN. HSP27 phosphorylation and interaction with actin-myosin in
smooth muscle contraction. Am J Physiol. 2002;282:G894–G903.
17. Connolly EM, Kelly CJ, Chen G, et al. Pharmacological induction of
HSP27 attenuates intimal hyperplasia in vivo. Eur J Vasc Endovasc Surg.
2003;25:40–47.
18. Park KJ, Gaynor RB, Kwak YT. HSP27 association with the I kappa B
kinase complex regulates tumor necrosis factor alpha-induced NF-kB
activation. J Biol Chem. 2003;278:35272–35278.
19. Garrido C, Gurbuxani S, Ravagnan L, et al. Heat shock proteins: endog-
enous modulators of apoptotic cell death. Biochem Biophys Res Commun.
2001;286:433–442.
Figure 2. HSP27 expression in human arteries. Immunostaining for
HSP27 (A and C) and VSMC -actin (B and D) in serial sections of
carotid atherosclerotic plaques (top) and mammary controls (bottom).
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